Patents by Inventor Jae Eun Kwak

Jae Eun Kwak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treatment of GM1 gangliosidosis
    Patent number: 10035830
    Abstract: The present invention relates to a method for preparing a GM1 gangliosidosis human cell model based on induced pluripotent stem cells (iPSCs) and iPSCs originated neural progenitor cells, and a use of the GM1 model above for the development of a GM1 gangliosidosis treating agent. The iPSCs originated from GM1 patient fibroblasts can be differentiated into neural progenitor cells (NPCs) and neurosphere cells that can emulate the characteristics shown in GM1 patient, so that the said cells can be efficiently used for the investigation of intracellular GM1 symptoms such as the GM1 gangliosidosis and lysosome accumulation and the gene expression pattern change. So, the GM1 cell model of the present invention can be efficiently used for the study of GM1 development mechanism and the study for the development of a therapeutic agent for the disease.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: July 31, 2018
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Yee Sook Cho, Mi Young Son, Jae Eun Kwak, Binna Seol, Hye Jin Jeon
  • GM1 GANGLIOSIDOSIS HUMAN CELL MODEL AND USE THEREOF
    Publication number: 20160069865
    Abstract: The present invention relates to a method for preparing a GM1 gangliosidosis human cell model based on induced pluripotent stem cells (iPSCs) and iPSCs originated neural progenitor cells, and a use of the GM1 model above for the development of a GM1 gangliosidosis treating agent. The iPSCs originated from GM1 patient fibroblasts can be differentiated into neural progenitor cells (NPCs) and neurosphere cells that can emulate the characteristics shown in GM1 patient, so that the said cells can be efficiently used for the investigation of intracellular GM1 symptoms such as the GM1 gangliosidosis and lysosome accumulation and the gene expression pattern change. So, the GM1 cell model of the present invention can be efficiently used for the study of GM1 development mechanism and the study for the development of a therapeutic agent for the disease.
    Type: Application
    Filed: August 6, 2015
    Publication date: March 10, 2016
    Applicant: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Yee Sook Cho, Mi Young Son, Jae Eun Kwak, Binna Seol, Hye Jin Jeon
  • METHOD FOR TREATMENT OF GM1 GANGLIOSIDOSIS
    Publication number: 20160068580
    Abstract: The present invention relates to a method for preparing a GM1 gangliosidosis human cell model based on induced pluripotent stem cells (iPSCs) and iPSCs originated neural progenitor cells, and a use of the GM1 model above for the development of a GM1 gangliosidosis treating agent. The iPSCs originated from GM1 patient fibroblasts can be differentiated into neural progenitor cells (NPCs) and neurosphere cells that can emulate the characteristics shown in GM1 patient, so that the said cells can be efficiently used for the investigation of intracellular GM1 symptoms such as the GM1 gangliosidosis and lysosome accumulation and the gene expression pattern change. So, the GM1 cell model of the present invention can be efficiently used for the study of GM1 development mechanism and the study for the development of a therapeutic agent for the disease.
    Type: Application
    Filed: August 6, 2015
    Publication date: March 10, 2016
    Applicant: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Yee Sook Cho, Mi Young Son, Jae Eun Kwak, Binna Seol, Hye Jin Jeon